Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Other Non Operating Income (2023 - 2025)

CG Oncology's Other Non Operating Income history spans 3 years, with the latest figure at -$53000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 983.33% year-over-year to -$53000.0; the TTM value through Dec 2025 reached -$152000.0, down 5166.67%, while the annual FY2025 figure was -$152000.0, 5166.67% down from the prior year.
  • Other Non Operating Income reached -$53000.0 in Q4 2025 per CGON's latest filing, up from -$100000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $8000.0 in Q1 2023 to a low of -$100000.0 in Q3 2025.
  • Average Other Non Operating Income over 3 years is -$17583.3, with a median of -$4000.0 recorded in 2023.
  • Peak YoY movement for Other Non Operating Income: surged 250.0% in 2024, then tumbled 4900.0% in 2025.
  • A 3-year view of Other Non Operating Income shows it stood at -$4000.0 in 2023, then soared by 250.0% to $6000.0 in 2024, then tumbled by 983.33% to -$53000.0 in 2025.
  • Per Business Quant, the three most recent readings for CGON's Other Non Operating Income are -$53000.0 (Q4 2025), -$100000.0 (Q3 2025), and -$4000.0 (Q2 2025).